The high attrition rates in clinical drug development and more especially in the late-stages drug clinical development is among the major challenges facing the pharmaceutical industry since failures in late-stage of clinical development are the costliest. The multitude of risks inherent in clinical drug development makes Go/No- Go decisions even more complex for pharmaceutical portfolio […]
Read More